Hence, dual inhibition of the COX-LOX [49] pathway could be advantageous in limiting inflammation when compared to the conventional NSAIDs; moreover, such a blockade of both pathways may also reduce incidences of gastric ulceration. This evidence concerns the gene LOX and gastric ulcer.